Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer
Status:
Completed
Trial end date:
2020-07-17
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ipilimumab when given after
chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer.
Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink
tumors. Monoclonal antibodies, such as ipilimumab, may find tumor cells and help carry
tumor-killing substances to them. Giving ipilimumab together with chemoradiation therapy may
be a better way treat cervical cancer.